Blood test could predict future risk of leukemia, study finds
Leukemia is often the result of the disruption to the fine balance in blood cell production where new cells are manufactured and old blood cells die.
Jul 5, 2022
0
57
Leukemia is often the result of the disruption to the fine balance in blood cell production where new cells are manufactured and old blood cells die.
Jul 5, 2022
0
57
Researchers from Rice University and the University of Texas MD Anderson Cancer Center have discovered potential new drugs that work in concert with other drugs to deliver a deadly one-two punch to leukemia.
Jun 30, 2022
0
65
A team of researchers at the University of Southern California, Los Angeles has found that acoustic tweezers can be used to deform leukemia cells in useful ways. In their paper published in IEEE Transactions on Ultrasonics, ...
Dysfunction involving an unusual type of thymocyte cell found in small amounts in every person may be the reason why some people develop a form of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) that affects more ...
Jun 27, 2022
0
80
New research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications—the so-called epigenetics—of a type of its genetic material: ...
Jun 9, 2022
0
10
Leukemia starts in cells that would normally develop into different types of blood cells. About 61,000 people in the U.S. are diagnosed each year, and depending on the type of leukemia and the age of the patient, five-year ...
Jun 8, 2022
0
27
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, ...
Jun 2, 2022
0
77
Survival has improved greatly in children with acute lymphocytic leukemia (ALL). But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic ...
Jun 1, 2022
0
35
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS), and increasingly in other diseases, but their mechanism of action is not clear. HMAs may affect many ...
May 26, 2022
0
18
A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART) using base editing, which ...
May 23, 2022
0
25